Cuorips Inc. AI Stock Analysis
Want to see JP:4894 full AI Analyst Report?
Cuorips Inc. (4894) AI Stock Analysis
Cuorips Inc.
(TSE/TYO:4894)
Financial performance drives the score with a solid balance sheet mitigating losses and cash burn risks. Positive technical trends add support, but poor valuation due to negative earnings caps the overall rating.
Cuorips Inc. (4894) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 58.77B
- Dividend Yield
- ―
- Average Volume (3M)
- 141.59K
- Price to Earnings (P/E)
- -47.9
- Beta (1Y)
- 1.22
- Revenue Growth
- -79.99%
- EPS Growth
- -58.51%
- Country
- Japan
- Employees
- 51
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Cuorips Inc. Business Overview & Revenue Model
Company Description
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-based...
Cuorips Inc. Financial Statement Overview
Summary
Despite low income statement and cash flow scores from persistent losses and R&D spending, the debt-free balance sheet offers strong financial stability for a development-stage biotech company.
Income Statement
35NegativeBalance Sheet
85Very PositiveCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 128.59M | 212.33M | 175.21M | 23.10M | 38.28M | 13.91M |
| Gross Profit | 5.13M | 45.90M | 91.56M | -60.47M | -57.64M | -82.09M |
| EBITDA | -1.12B | -996.81M | -513.57M | -518.38M | -371.78M | -280.46M |
| Net Income | -1.14B | -1.02B | -644.34M | -632.18M | -452.08M | -375.34M |
Balance Sheet | ||||||
| Total Assets | 4.81B | 5.12B | 5.74B | 6.18B | 3.59B | 4.04B |
| Cash, Cash Equivalents and Short-Term Investments | 3.32B | 3.90B | 4.79B | 5.58B | 2.94B | 3.34B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 354.46M | 353.83M | 211.91M | 200.96M | 133.79M | 149.36M |
| Stockholders Equity | 4.44B | 4.75B | 5.53B | 5.98B | 3.45B | 3.90B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.10B | -892.81M | -474.83M | -412.18M | -249.45M |
| Operating Cash Flow | 0 | -1.06B | -812.62M | -451.06M | -401.61M | -220.76M |
| Investing Cash Flow | 0 | -7.59M | -117.99M | -33.50M | -8.97M | -28.44M |
| Financing Cash Flow | 0 | 176.84M | 143.11M | 3.12B | 10.69M | 48.54M |
Cuorips Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Positive. The current price of 6620.00 is below the 20-day moving average (MA) of 6674.00, above the 50-day MA of 6187.80, and above the 200-day MA of 6121.48, indicating a neutral trend. The MACD of 128.55 indicates Positive momentum. The RSI at 51.59 is Neutral, neither overbought nor oversold. The STOCH value of 54.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4894.
Cuorips Inc. Peers Comparison
Overall Rating
JP:489454Neutral
JP:497844Neutral
JP:777442Neutral
JP:459339Underperform
JP:459938Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | JPY 58.79B | -47.85 | ― | ― | -79.99% | -58.51% | |
| 44Neutral | JPY 11.65B | -25.06 | ― | ― | -8.23% | -48.10% | |
| 42Neutral | JPY 26.52B | -73.78 | ― | ― | 17.05% | 10.47% | |
| 39Underperform | JPY 30.90B | -13.76 | ― | ― | -51.55% | 52.19% | |
| 38Underperform | JPY 7.33B | -3.94 | ― | ― | ― | 4.85% | |
| 37Underperform | JPY 6.70B | -5.83 | ― | ― | -49.43% | -3.77% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4894 | Cuorips Inc. | 6620.00 | 210.00 | 3.28% | |
| JP:4593 | Healios KK | 228.00 | -223.00 | -49.45% | |
| JP:4599 | StemRIM Inc. | 117.00 | -161.00 | -57.91% | |
| JP:4978 | ReproCELL Inc. | 109.00 | -48.00 | -30.57% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 653.00 | 175.00 | 36.61% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026
